This, coupled with our findings that the effects of PRMT inhibitors depend on the expression of EWSR1::FLI1, indicate that drug treating ES patients with PRMT inhibitors, with or without PARP inhibitors, offers a potential new therapeutic approach. The gene discussed is PARP1; the disease is Ewing sarcoma.